Real-World Experience with Maribavir for Treatment of Cytomegalovirus Infection in High-Risk Solid Organ Transplant Recipients

Bin Ni; Cameron R. Wolfe; Sana Arif; Manuela Carugati; Madeleine R. Heldman; Julia A. Messina; Rachel A. Miller; Jennifer L. Saullo; Arthur W. Baker; Eileen K. Maziarz

doi:10.1093/ofid/ofae335

Real-World Experience with Maribavir for Treatment of Cytomegalovirus Infection in High-Risk Solid Organ Transplant Recipients

Bin Ni, Cameron R. Wolfe, Sana Arif, Manuela Carugati, Madeleine R. Heldman, Julia A. Messina, Rachel A. Miller, Jennifer L. Saullo, Arthur W. Baker, Eileen K. Maziarz

Research output: Contribution to journal › Article › peer-review

17 Scopus citations

Abstract

We evaluated use of maribavir (MBV) for treatment of 15 episodes of refractory/resistant cytomegalovirus infection in 13 solid organ transplant recipients. Treatment failure due to treatment-emergent MBV resistance or early virological recurrence after MBV discontinuation occurred in 7 (47%) episodes. Sustained viral clearance was achieved in 6 (40%) episodes.

Original language	English (US)
Article number	ofae335
Journal	Open Forum Infectious Diseases
Volume	11
Issue number	7
DOIs	https://doi.org/10.1093/ofid/ofae335
State	Published - Jul 1 2024

Keywords

antiviral drug resistance
antiviral therapy
cytomegalovirus
maribavir
solid organ transplantation

ASJC Scopus subject areas

Oncology
Infectious Diseases

Access to Document

10.1093/ofid/ofae335

Cite this

@article{d03cd22406e446a5a5b1346535e6f4e9,

title = "Real-World Experience with Maribavir for Treatment of Cytomegalovirus Infection in High-Risk Solid Organ Transplant Recipients",

abstract = "We evaluated use of maribavir (MBV) for treatment of 15 episodes of refractory/resistant cytomegalovirus infection in 13 solid organ transplant recipients. Treatment failure due to treatment-emergent MBV resistance or early virological recurrence after MBV discontinuation occurred in 7 (47\%) episodes. Sustained viral clearance was achieved in 6 (40\%) episodes.",

keywords = "antiviral drug resistance, antiviral therapy, cytomegalovirus, maribavir, solid organ transplantation",

author = "Bin Ni and Wolfe, \{Cameron R.\} and Sana Arif and Manuela Carugati and Heldman, \{Madeleine R.\} and Messina, \{Julia A.\} and Miller, \{Rachel A.\} and Saullo, \{Jennifer L.\} and Baker, \{Arthur W.\} and Maziarz, \{Eileen K.\}",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2024.",

year = "2024",

month = jul,

day = "1",

doi = "10.1093/ofid/ofae335",

language = "English (US)",

volume = "11",

journal = "Open Forum Infectious Diseases",

issn = "2328-8957",

publisher = "Oxford University Press",

number = "7",

}

TY - JOUR

T1 - Real-World Experience with Maribavir for Treatment of Cytomegalovirus Infection in High-Risk Solid Organ Transplant Recipients

AU - Ni, Bin

AU - Wolfe, Cameron R.

AU - Arif, Sana

AU - Carugati, Manuela

AU - Heldman, Madeleine R.

AU - Messina, Julia A.

AU - Miller, Rachel A.

AU - Saullo, Jennifer L.

AU - Baker, Arthur W.

AU - Maziarz, Eileen K.

N1 - Publisher Copyright: © The Author(s) 2024.

PY - 2024/7/1

Y1 - 2024/7/1

N2 - We evaluated use of maribavir (MBV) for treatment of 15 episodes of refractory/resistant cytomegalovirus infection in 13 solid organ transplant recipients. Treatment failure due to treatment-emergent MBV resistance or early virological recurrence after MBV discontinuation occurred in 7 (47%) episodes. Sustained viral clearance was achieved in 6 (40%) episodes.

AB - We evaluated use of maribavir (MBV) for treatment of 15 episodes of refractory/resistant cytomegalovirus infection in 13 solid organ transplant recipients. Treatment failure due to treatment-emergent MBV resistance or early virological recurrence after MBV discontinuation occurred in 7 (47%) episodes. Sustained viral clearance was achieved in 6 (40%) episodes.

KW - antiviral drug resistance

KW - antiviral therapy

KW - cytomegalovirus

KW - maribavir

KW - solid organ transplantation

UR - https://www.scopus.com/pages/publications/85197497030

UR - https://www.scopus.com/inward/citedby.url?scp=85197497030&partnerID=8YFLogxK

U2 - 10.1093/ofid/ofae335

DO - 10.1093/ofid/ofae335

M3 - Article

AN - SCOPUS:85197497030

SN - 2328-8957

VL - 11

JO - Open Forum Infectious Diseases

JF - Open Forum Infectious Diseases

IS - 7

M1 - ofae335

ER -

Real-World Experience with Maribavir for Treatment of Cytomegalovirus Infection in High-Risk Solid Organ Transplant Recipients

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this